Sign Out
SR tab: As with all narcotics, a reduction of dosage may be advisable in the elderly, in renal and chronic hepatic disease, Hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy or urethral stricture, acute alcoholism, delirium tremens, hyposcoliosis.
Morphine produces effects which may obscure neurologic signs of further increases in pressure in patients with head injuries.
Morphine Sulfate Pentahydrate Tablets like all opioid analgesics, should be administered with caution to patients in circulatory shock, since vasodilatation produce by the drug may further reduce cardiac output and blood pressure.
Morphine may obscure the diagnosis or clinical course in patients with acute abdominal conditions.
Caution should be given in patients about to undergo surgery of the biliary tract, since it may cause spasm of the sphincter of Oddi. Similarly, morphine should be used with caution in patients with acute pancreatitis secondary to biliary tract disease.
Morphine has a well recognized abuse and addiction profile similar to other strong opioids.
Tolerance to analgesic effects may develop upon repeated administration. Physical dependence can develop during repeated administration; cessation of medication or the application of an opioid antagonist may induce withdrawal symptoms.
Morphine may lower the threshold inpatients with a history of epilepsy. Morphine has to administered with caution to patients with a history of substance abuse, raised intracranial pressure, hypo tension with hypovolemia, biliary tract disorders, pancreatitis, severe renal dysfunction, severe chronics obstructive lung disease, severe cor pulmonale, severe bronchial asthma and respiratory depression.
Low levels of morphine have been detected in breast milk. Withdrawal symptoms can occur in breast fed infants when maternal administration of morphine sulphate is stopped. Ordinary nursing should not be undertaken while a patient is receiving Morphine Sulfate Pentahydrate Tablets, since morphine may be excreted in the milk.
As with all morphine preparations, patients who are to undergo cordotomy or other pain relieving surgical procedures should not receive Morphine Sulfate Pentahydrate Tablets for 24 hours prior to surgery. If further treatment with Morphine Sulfate Pentahydrate Tablets is then indicated, the dosage should be adjusted to the new post-operative requirement.
Further Information: Morphine sulfate is readily absorbed from the gastrointestinal tract following oral administration.
The patented controlled release system maintains plasma levels of morphine over a period of up to twelve hours and reduces the likelihood of morphine associated side effects.
Morphine may impair the ability to drive and use machines.
Transferability: It is not possible to ensure bioequivalence between different controlled release morphine products.
Therefore, it should be emphasized that patients, once titrated to an effective dose, should not be changed from Morphine Sulfate Pentahydrate Tablets preparations to other slow, sustained or controlled release morphine preparation without retitration and clinical assessment.
Syr: Should be used with caution in patients with controlled asthma. Patients should be closely monitored for any signs of misuse, abuse, or addiction. Withdrawal syndrome may occur upon abrupt discontinuation treatment or abrupt dose reduction. Used with caution in patients with liver disease. Doses should be reduced in chronic liver and kidney disease, severe hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy or shock. Monitoring for any symptoms of acute chest syndrome. May cause hypogonadism and adrenal insufficiency in male and females.
Effects on the ability to drive or operate machinery: May impair the ability to drive the vehicle or operate the machinery.
Lanjutkan dengan Google